Prostate Cancer Consortium Partners with Tech Company Tempus for Trial Examining DNA Abnormalities

Prostate Cancer Consortium Partners with Tech Company Tempus for Trial Examining DNA Abnormalities
The Prostate Cancer Clinical Trials Consortium (PCCTC) has partnered with technology company Tempus to advance its Phase 2 clinical trial to identify the most effective treatment for prostate cancer in patients with genomic evidence of DNA repair problems. Tempus will screen the genomes of potential participants and analyze data from the study. The trial (NCT03012321) is a randomized, Phase 2 study evaluating Lynparza (olaparib) plus prednisone, Zytiga (abiraterone ac
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *